• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Oncocyte Corp (NQ: OCX )

    3.085 -0.075 (-2.37%)
    Streaming Delayed Price Updated: 10:20 AM EDT, Aug 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Oncocyte Corp

    < Previous 1 2 3 4 Next >
    OCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024
    OCX stock results show that OncoCyte beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    OncoCyte’s (NASDAQ:OCX) Innovative Approach: Potential in Precision Diagnostics
    Via AB Newswire
    OncoCyte's Innovative Approach: Potential in Precision Diagnostics
    OncoCyte's Innovative Approach: Potential in Precision Diagnostics 
    Via News Direct
    OncoCyte's Innovative Approach: Potential in Precision Diagnostics
    Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For... 
    Via TheNewswire.com
    4 Analysts Assess OncoCyte: What You Need To Know
    Via Benzinga
    OncoCyte's Earnings: A Preview
    Via Benzinga
    Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier
    Via ACCESSWIRE
    Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
    Via ACCESSWIRE
    OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q1 2024
    OCX stock results show that OncoCyte missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    3 Penny Stocks That Insiders Are Buying
    Penny stocks are a risky business but following the insiders to your next trade can alleviate some of the risks; these are the three hottest insider buys. 
    Via MarketBeat
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning! 
    Via InvestorPlace
    Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage
    Via ACCESSWIRE
    Oncocyte Reports Second Quarter 2023 Financial Results
    Via ACCESSWIRE
    Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference
    Via ACCESSWIRE
    Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
    Via Benzinga
    Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
    Shares of Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced that it sold its majority interest in Utah Hospitals. 
    Via Benzinga
    Oncocyte To Announce Second Quarter 2023 Financial Results
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023
    OCX stock results show that OncoCyte missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    Top 3 Health Care Stocks That May Collapse In Q2
    As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Friday is here and we're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning! 
    Via InvestorPlace
    Earnings Scheduled For April 12, 2024
    Companies Reporting Before The Bell • Progressive (NYSE:PGR) is projected to report quarterly earnings at $3.17 per share on revenue of $17.43 billion. 
    Via Benzinga
    Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
    Shares of NextPlat Corp (NASDAQ: NXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results. 
    Via Benzinga
    Oncocyte Regains Compliance With Nasdaq Listing Requirements
    Via ACCESSWIRE
    Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. 
    Via Benzinga
    Earnings Scheduled For August 10, 2023
    Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.